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Decreased Na+, K+-ATPase (NKA) activity causes energy deficiency, which is commonly
observed in neurodegenerative diseases. The NKA is constituted of three subunits: α, β,
and γ, with four distinct isoforms of the catalytic α subunit (α1−4). Genetic mutations in the
ATP1A2 gene and ATP1A3 gene, encoding the α2 and α3 subunit isoforms, respectively
can cause distinct neurological disorders, concurrent to impaired NKA activity. Within
the central nervous system (CNS), the α2 isoform is expressed mostly in glial cells
and the α3 isoform is neuron-specific. Mutations in ATP1A2 gene can result in familial
hemiplegic migraine (FHM2), while mutations in the ATP1A3 gene can cause Rapid-onset
dystonia-Parkinsonism (RDP) and alternating hemiplegia of childhood (AHC), as well
as the cerebellar ataxia, areflexia, pescavus, optic atrophy and sensorineural hearing
loss (CAPOS) syndrome. Data indicates that the central glutamatergic system is
affected by mutations in the α2 isoform, however further investigations are required to
establish a connection to mutations in the α3 isoform, especially given the diagnostic
confusion and overlap with glutamate transporter disease. The age-related decline in
brain α2/3 activity may arise from changes in the cyclic guanosine monophosphate
(cGMP) and cGMP-dependent protein kinase (PKG) pathway. Glutamate, through
nitric oxide synthase (NOS), cGMP and PKG, stimulates brain α2/3 activity, with the
glutamatergic N-methyl-D-aspartate (NMDA) receptor cascade able to drive an adaptive,
neuroprotective response to inflammatory and challenging stimuli, including amyloid-β.
Here we review the NKA, both as an ion pump as well as a receptor that interacts with
NMDA, including the role of NKA subunits mutations. Failure of the NKA-associated
adaptive response mechanisms may render neurons more susceptible to degeneration
over the course of aging.
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INTRODUCTION
Na+, K+-ATPase
In 1957, the Danish physician Jens C. Skou discovered
the mechanism behind active ion transport in homogenates
of leg nerve from shore crabs: a Mg2+-dependent ATPase
stimulated by Na+ and K+, speculated to be located at the
plasma membrane (Skou, 1957). In the same year that Skou
published his ATPase work, Robert L. Post and Philip Jolly
showed that interdependent active Na+ eﬄux and K+ influx
followed an electrogenic stoichiometry of 3:2 (Post and Jolly,
1957), an exchange previously shown to be blocked by the
cardiotonic steroid (CTS) isolated from plant species of the genus
Strophanthus, strophantin, widely known as ouabain (OUA)
(Schatzmann, 1953; Schatzmann and Witt, 1954). In 1960, Post
and colleagues demonstrated the presence of Na+, K+-ATPase
(NKA) in the plasma membrane of human red blood cells
(Post et al., 1960),including its transient phosphorylation by
ATP on an aspartyl residue (Post et al., 1965; Post and Kume,
1973). Subsequent work indicated a feed-forward reaction,
whereby as Na+ binds to the enzyme, it stimulates a Mg2+-
dependent phosphorylation via ATP, while K+ binding facilitates
dephosphorylation, giving a transition of two conformations
named E1 and E2, respectively (Post et al., 1972). Later work
made it clear that activity of this molecular motor is vital for
cell integrity, given its maintenance of the osmotic balance
and its powerful role in cell homeostasis, including preserving
and contributing to the resting membrane potential, electrolyte
constitution of the cerebrospinal fluid (CSF) and influencing
the cellular and/or transcellular transport of other ions, energy
substrates and neurotransmitters (Blanco and Mercer, 1998;
Skou, 1998; Blanco, 2005).
The enzyme is composed of two distinct polypeptides (Kyte,
1971), with equimolar stoichiometry (Craig and Kyte, 1980).
The larger one is the α subunit, with an amino acid sequence
(>1010 amino acids) that was first deduced from sheep kidney
complementary DNA in 1985 by Jerry Lingrel’s group (Shull
et al., 1985). The α subunit has a mass of 110–112 kDa,
with 10 transmembrane domains, mostly with protein resides
in the cytoplasm side and with less than 10% exposed to
the extracellular milieu (Blanco, 2005). The α subunit is also
known as the catalytic or functional subunit, since it contains
the binding sites for Na+ and K+, as well as for CTS. The
α subunit is subject to transient phosphorylation and breaks
down Mg2+-ATPase (Kyte, 1975; Blanco, 2005). The smaller
β subunit is a type II (one transmembrane domain with
intracellular N-terminal) glycoprotein of 302–304 amino acids
that noncovalently binds to the α subunit (Shull et al., 1985).
Although the α subunit can display independent ATP catalysis
(Blanco et al., 1994), it is only when it is associated with the
β subunit that normal pumping activity is achieved. The β
subunit also influences the NKA kinetic characteristics, assisting
the correct assembly and membrane delivery of the enzyme
(chaperone function), as well as helping in cell adhesion and cell
polarity (Blanco, 2005; Geering, 2008; Cereijido et al., 2012; Vagin
et al., 2012). A third partner comprises the αβ protomer (formerly
termed the γ subunit) (Forbush et al., 1978). This type I (one
transmembrane domain with intracellular C-terminal) protein
is small—around 65 amino acids, with a mass of 7 kDa—and
belongs to the FXYD family of ion transport regulators. FXYD
represents the signature motif found in all 7 members. FXYD2
is the original γ subunit, although all can interact with NKA
(Geering, 2008). However, they are not necessary for enzymatic
activity, modulating, usually decreasing, pump affinity for cations
(Geering, 2006, 2008).The electrophoresis technique has unveiled
puzzling pharmacological data that demonstrate differences in
the potency and affinity of CTS for NKA, when NKA is derived
from different tissues and species (Akera et al., 1972; Tobin and
Brody, 1972; De Pover and Godfraind, 1976, 1979; Marks and
Seeds, 1978; Noel and Godfraind, 1984). By the end of 1970’s,
Kathlyn Sweadner demonstrated in brain preparations of several
mammalian species that two protein bands of slightly different
molecular weights could be clearly defined, with the biochemical
characteristics of NKA (Sweadner, 1979). The kidney α subunit
co-migrated with the brain lower migrating (lighter) band in
gel and was designated α (now α1), with the other brain band,
heavier and not present in kidney, designated α(+) (Sweadner
and Gilkeson, 1985). A third form was revealed from rat brain
cDNA sequence analysis and named αIII (now α3), a major form
in the central nervous system (CNS) (Shull et al., 1986; Schneider
et al., 1988; Sweadner, 1989). α(+) was indeed a mixture of
α2 and α3. Years later, a fourth α isoform was discovered and
characterized (Shamraj and Lingrel, 1994; Woo et al., 1999;
Blanco et al., 2000). All isoforms are encoded by different genes,
have a high degree of sequence homology and are expressed in a
cell/tissue-specific manner (Broude et al., 1989; Mobasheri et al.,
2000; Blanco, 2005): α1 is expressed in all mammalian tissue,
being virtually the only α isoform expressed in the kidney across
species; α2 is found in striated and smooth muscles, adipose
tissue, nervous tissue and some other tissues; α3 and α4 have
a more restricted distribution, with the former being primarily
found in nervous tissue, more specifically in neurons, where
it may be considered a brain neuronal marker (Dobretsov and
Stimers, 2005), and the latter is only expressed in the midpiece
of the sperm, where it is important for sperm motility (Sanchez
et al., 2006).
A Pump or a Receptor: The Janus Face of
an ATPase
NKA has been classically conceptualized as a pump, with its
specific inhibition by CTS that increases intracellular Na+ and
Ca2+ concentrations leading to cell ionic imbalance (Akera and
Brody, 1977). This was challenged by a series of elegant studies
headed by Zi-Jian Xie and Amir Askari 20 years ago. These
researchers observed that OUA induced myocyte hypertrophy
by activating proto-oncogenes and late response genes, with
effects mediated by the Ras-Raf-ERK1/2-pathway (Peng et al.,
1996; Huang L. et al., 1997; Kometiani et al., 1998). This was
preceded by EGFR transactivation through the nonreceptor Tyr
kinase, Src, steps not dependent on Ca2+(Haas et al., 2000).
Such signal transducer pump effects arise from activity in
restricted areas of the plasma membrane, within a subset of
lipid rafts known as caveolae (Liu et al., 2003; Wang et al.,
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2004; Quintas et al., 2010). NKA (E1 state) can interact with
Src at the kinase and SH3 domain with OUA, by arresting
the E2 conformation of the ATPase, unleashing the kinase
domain of Src, thereby inducing protein-protein signaling (Liang
et al., 2006; Tian et al., 2006; Ye et al., 2013). As such, NKA-
Src forms a binary receptor that transduces signals after CTS
binding.
After the first reports on the novel signaling role of NKA, a
number of different intracellular pathways involved in distinct
cell fates has been unveiled, confirming NKA as more than an
ion pump (Nesher et al., 2007; Cai et al., 2008; Riganti et al.,
2011; Arnaud-Batista et al., 2012; Lucas et al., 2012) and helping
to clarify how endogenous CTS can produce their effects in vivo,
even at very low concentrations (Xie and Xie, 2005; Aperia et al.,
2016).
NKA Mutations and Diseases
Considering the importance of NKA in basic cellular functions, it
has been suggested that NKA mutations affecting α1 (ATP1A1),
α2 (ATP1A2), and α3 (ATP1A3) genes can contribute to the
pathogenesis of several CNS diseases.
ATP1A1 Mutations
Mutation in the ATP1A1 gene leads to primary aldosteronism
(Azizan et al., 2013), which is the main cause of secondary
hypertension. Aldosterone production is elevated and non-
suppressible by sodium loading (Duan and Mete, 2015). The
mutation causes a decrease in NKA activity and in K+ affinity,
consequently leading to an inappropriate cellular depolarization
(Beuschlein et al., 2013). Primary aldosteronism can also be
caused by mutations in ATP2B3 (Ca2+-ATPase), CACNA1D
(Cav1.3), and KCNJ5 (K+ channel) (Azizan et al., 2013; Zennaro
et al., 2015). In a study with 474 patients, ATP1A1 mutation was
found in 5.3% of the sample, although the relationship between
the disorder and the ATP1A1 mutation was only discovered
recently, requiring further investigations as to the mechanism
involved (Fernandes-Rosa et al., 2014).
ATP1A3 Mutations
ATP1A3 is only expressed in CNS neurons, mostly in the
cerebellum and basal ganglia, key structures in the regulation
of a range of functions, including motor activity, memory and
spatial learning. The ATP1A3 mutations are common in the
conserved transmembrane or N-terminus domain of NKA and
are related to rare disorders, such as rapid-onset dystonia-
parkinsonism (RDP), alternating hemiplegia of childhood
(AHC), and cerebellar ataxia, areflexia, pescavus, optic atrophy,
and sensorineural hearing loss (CAPOS) syndrome. Although
having many common features, these three diseases have quite
distinct phenotypes (Sweney et al., 2015).
RDP (or DYT12) is a type of dystonia, being classed as
a hyperkinetic movement disorder. RDP onset can be highly
variable, occurring from 18 months to 55 years, suggesting
considerable heterogeneity in its pathophysiology (Sweney et al.,
2015). The main features are involuntary muscle contractions,
abnormal posture and repetitive movements. RDP was first
linked to ATP1A3 mutations by De Carvalho Aguiar and
colleagues in 2004 (de Carvalho Aguiar et al., 2004), having
an autosomal dominant inheritance. However, this disorder can
also be sporadic or not related to any mutation in ATP13A
(Kabakci et al., 2005). Although some RDP symptoms resemble
Parkinson’s disease, with both disorders showing evidence
of abnormal CSF dopamine metabolites, RDP patients are
unresponsive to deep brain stimulation (Charlesworth et al.,
2013) or to L-DOPA treatment (Asmus and Gasser, 2010). RDP
differentiation from Parkinson’s disease is based on: triggering by
physical or emotional stress, abrupt onset, bulbar involvement
and normal computed tomography in the striatum (Zanotti-
Fregonara et al., 2008; Asmus and Gasser, 2010).
Twelve mutations are associated with RDP, each being related
to different severity levels. RDP treatment is only symptomatic,
mostly utilizing benzodiazepines (Sweney et al., 2015). The
T613M mutation is the most common and with the most severe
outcome. Psychiatric conditions, such as bipolar disorder and
anxiety, seem to be related to RDP (Barbano et al., 2012). A
growing variety of clinical presentations have been reported in
association with these mutations, including episodes of flaccidity
and lack of motion for hours leading to stiffness (Anselm et al.,
2009) or delayed motor development and hypotonia that lead to
a uncoordinated gait, as well as speech and swallowing difficulties
in R756H and D823N mutations.
Recent studies on a family with RDP, where only women
present with a symptomatic phenotype, indicate a new mutation
that causes a deletion (c.443_445delGAG, p.Ser148del). A male
member from the same family also carries the p.Ser148del
mutation, but he does not have any symptoms, suggesting a
reduced penetrance of this mutation (Wilcox et al., 2015). RDP
patients are still commonly misdiagnosed, indicating the need
to incorporate new features in order to make an appropriate
diagnosis (Brashear et al., 2012).
The onset of motor symptoms in RDP patients occurs usually
by 25 years of age, with initial symptoms occurring in the upper
body. Following initial diagnosis, patients have been shown to
have poor learning, memory and psychomotor speed vs. controls
(Cook et al., 2014). This would seem to arise from α3 being
highly expressed in all nuclei of the basal ganglia and cerebellum,
which are important regions for the control of movement, and
in the hippocampus, which is crucial to spatial learning and
memory (Oblak et al., 2014). Experiments utilizing in vitro
and in vivo models have investigated the alterations driven by
these mutations, including the role of impaired NKA activity.
A C-terminus protein mutation decreases Na+ affinity, although
no abnormality in biogenesis or plasma membrane targeting was
found. Also, a decreased survival in these neuronal cells was
observed when they were treated with OUA (Blanco-Arias et al.,
2009).
Other mutations were also tested in COS7 cells, with no
phosphorylation from ATP and low Na+ affinity being detected
in most mutations. Consequently, increased intracellular Na+
and decreased extracellular K+ were observed. Thus, the affinity
of Na+ may be an important concern in RDP (Toustrup-Jensen
et al., 2014) (Figure 1). In mutated α3 mice (Het mice), stress
exposure was capable of causing motor and balance deficits
characteristic of RDP (DeAndrade et al., 2011). These authors
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FIGURE 1 | Schematic representation of the influence of ATP1A2mutations in glia and ATP1A3mutations in neurons on glutamatergic system activity.
Mutations cause a dysfunctional NKA activity, (A) ATP1A3 mutation in neurons decreases the NKA activity and increases intracellular Na+, which increases the cellular
excitability, thereby affecting neuronal functions. Flumarazine and topiramate could be used as treatment in some cases. (B) ATP1A2 in astrocytes results in change of
metabolism, more K+, and glutamate in the extracellular space and rendering the CNS more vulnerable to migraine, seizures, and neurodegenerative process.
also showed significant alterations in monoamine metabolism
and thermal sensitivity in this model (DeAndrade et al., 2011).
AHC is a neurodevelopmental disorder described initially
in 1971 by Verret and Steele (1971). However, it was only in
2012 that AHC was discovered to be a heterozygous ATP1A3
de novo mutation (Heinzen et al., 2012; Rosewich et al.,
2014). AHC patients present with an onset before the age of
18 months and following an environmental or physiological
stimulus, which is also present in RDP. AHC patients present
with motor delay and attacks of hemiplegia, as well as cognitive
and intellectual deficits (Sweney et al., 2015). AHC disorder
can be difficult to differential diagnosis especially in relation to
familial hemiplegic migraine (FHM) and glutamate transport
disease (Jen et al., 2005). Sleep can stop AHC attacks, although
even after sleep, attacks can return. Avoidance of the possible
triggers is also important to prophylaxis, whilst antiepileptic
drugs should only be used in patients showing status epilepticus
(Rosewich et al., 2014; Paciorkowski et al., 2015). Flunarizine is
a Ca2+ and Na+ channel blocker, which was developed to treat
migraine and is currently the main AHC treatment, although
the mechanism of action is unknown. Similarly, topiramate’s
mode of efficacy is unknown and may include its inhibition
of 2-amino-3-(3-hydroxyl-5-methyl-4-isoxazolyl) propionic acid
(AMPA) receptors and carbonic anhydrase, thereby lowering
extracellular pH (Hoei-Hansen Et al., 2014; Yang et al., 2014)
(Figure 1).
Another strategy used in AHC patients is the ketogenic
diet/modified Atkins diet, given that a family with the
p.Asp923Asn mutation was initially misdiagnosed as GLUT1DS
(glucose transporter deficiency syndrome), with 15 months of
diet management leading to no further attacks. A ketogenic diet
provides an alternative energy source for the brain and may
decrease neuroexcitability (Roubergue et al., 2015). In some cases,
when a patient has two mutations in SLC2A1 and ATP1A3,
flunarizine provides an incomplete response, with concurrent use
of a ketogenic diet improving the utility of flunarizine (Ulate-
Campos et al., 2014). A patient with c.2401G>A; p.D801N
mutation failed to respond to all the treatment strategies and only
the use of a corticosteroid achieved complete remission (Wong
and Kwong, 2015).
In Japan, the more severe phenotype arising from the
E815K mutation was found to be more common than in
other countries, occurring in 50% of investigated patients. The
more severe phenotype evident in these mutations includes:
earlier age of onset, more epileptic episodes and increased
motor impairment (Ishii et al., 2013). Usually patients with no
detectable mutation have less symptomatology (Hoei-Hansen
Et al., 2014), whilst an early onset of AHC symptoms seems
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positively correlated with a more severe clinical course (Viollet
et al., 2015).
A Danish study showed bilateral episodes to be common, with
hemiplegic episodes not always alternating. Consequently, the
term AHCmay not be the most appropriate (Hoei-Hansen Et al.,
2014). A recent study of 155 patients showed 34 mutations to
be related to AHC, with at least one being detected in 85% of
patients. The three major mutations were found p.Glu815Lys,
p.Asp801Asn, and p.Gly947Arg, with the first having the most
severe phenotype, as indicated by greater intellectual impairment
and motor disability. In contrast, p.Asp801Asn presents with
a milder phenotype, whilst p.Gly947Arg appears to have the
most favorable prognosis, in comparison to other mutations
(Panagiotakaki et al., 2015).
Some mutations show a symptomatology that indicates a
combination of RDP and AHC, including c.2600G>A, D923N
and R756 (Rosewich et al., 2014). The E277K and D923N
mutations have been described in both (Boelman et al.,
2014). The difference between RDP and AHC may be due
to different regions and cells affected by the mutations in
ATP13A, with differential impacts arising from effects within
a developmental context (Ozelius, 2012). Patients with epilepsy
had an earlier onset, although no relationship with a specific
mutation (Panagiotakaki et al., 2015). AHC patients have
electrocardiogram and repolarization abnormalities compared
to people with epilepsy, contributing to episodes of collapse
unrelated to seizures, as well as to some premature deaths
(Novy et al., 2014; Jaffer et al., 2015). Activated platelets from
AHC patients have functional and structural abnormalities,
with 93 proteins related to metabolism being differentially
expressed in comparison to healthy controls. Cathepsin B was
also more highly expressed, indicating an important role of
apoptotic pathway activation in driving mutation-associated cell
death (Di Michele et al., 2013). An AHC patient showing a
mutation in SLC2A1 p.Gly18Arg, which leads to the loss of
GLUT1 expression, was also diagnosedwith hemiplegicmigraine,
which can be related to increases in cortex glutamate levels. As
such, glutamate levels should also be investigated in mutation-
associated AHC patients (Weller et al., 2015).
Mutations of ATP1A3 that can be evident in AHC patients,
have been tested in Sf9 cells. OUA binding, NKA activity and
phosphorylation were measured for each mutant and were found
to be abnormal in I274N, E815K, and G947R mutations. Some
mutations showed normal bind to OUA, although no NKA
activity or phosphorylation were found. Such differences may
be associated with phenotype severity (Weigand et al., 2014).
In a murine AHC model, the D801N mutant mouse (Mashlool,
Mashl+/), a similar symptomatology is found as that evident
in AHC patients, including abnormalities in gait and motor
coordination, as well as spontaneous recurrent seizures and
hemiplegia. The study of hippocampal slices showed increased
excitability, which contributes to abnormal plasticity and a
predisposition to more spontaneous seizures (Hunanyan et al.,
2015).
Another animal model, the Myshkin (Myk) model, carries the
I810N mutation, which presents with a reduced threshold for
hippocampal seizures and neuronal loss. Although α3 is normally
expressed, NKA activity is reduced with a consequent reduction
in thalamocortical functional connectivity (Clapcote et al., 2009;
Kirshenbaum et al., 2013). This murine model is also used as a
model of bipolar disorder, with symptoms being improved by
melatonin and physical exercise (Kirshenbaum et al., 2014). An
α3 mutation is evident in the Atp1a3tm1Ling murine model,
leading to a reduction in hippocampal α3 expression, thereby
lowering NKA activity. Dystonia is only induced in this model
after kainate injection into the cerebellum (Ikeda et al., 2013).
In 1996, CAPOS syndrome was described, with only the
c.2452G> mutation in ATP1A3 being found in four families
studied. This is a gain-of-function mutation, which differs from
the loss mutations evident in RDP and AHC (Demos et al., 2014).
CAPOS is a rare syndrome associated with febrile illness, with
each patient differing in regard to severity and outcome (Sweney
et al., 2015). Recently, CAPOS syndrome has been shown to cause
hemiplegic migraine in a single case study (Potic et al., 2015).
ATP1A2 Mutations
Migraine is a brain disorder that affects over 10% of
the population, characterized by a headache associated with
neurological and autonomic symptoms. Moreover, it frequently
occurs as a pulsating and unilateral headache, usually followed by
phono/photophobia and nausea (Russell et al., 1994). Migraine
is thought to be initiated by brain dysregulation, leading to
activation and increased vulnerability of the trigeminovascular
system, mainly the trigeminal nociceptive afferents innervating
the meninges (Goadsby et al., 2002; Pietrobon and Striessnig,
2003; Pietrobon, 2005). Migraine disorders may be preceded,
or not, by neurological symptoms that are often visual, and
can therefore be classified as migraine with or without aura
(Pietrobon and Striessnig, 2003; Pietrobon, 2005). Clinical
studies indicate that migraine aura is related with a wave of
cortical spreading depression (CSD). CSD is a strong wave of
short duration of neuronal and glial cell depolarization, which
extends over the cortex and is accompanied by long-lasting
depression of neuronal activity (Lauritzen, 1994; Cutrer et al.,
1998; Bowyer et al., 2001; Hadjikhani et al., 2001). Studies have
shown a relationship between CSD and migraine aura in humans
and animal models and its importance to trigeminal activation
(Russell et al., 1994; Bowyer et al., 2001; Hadjikhani et al., 2001;
Bolay et al., 2002; Goadsby, 2002; Dalkara et al., 2006; Zhang et al.,
2010).
FHM is a special autosomal dominant subtype of migraine
with aura, characterized by some degree of motor frailty or
paralysis, often hemiparesis (Thomsen et al., 2002). Furthermore,
severe cases have been associated with symptoms such as
progressive cerebellar ataxia, coma, fever, and/or epileptic
seizures (Ducros et al., 1997). FHM is a genetically heterogeneous
disease, in which mutations can occur in the ion transportation
genes CACNA1A, ATP1A2, and SCN1A (Rogawski, 2008),
promoting the different types of familial migraines, FHM1,
FHM2 and FHM3 (Russell et al., 1994; Pierelli et al., 2006;
Deprez et al., 2008). FHM1 is induced bymutations inCACNA1A
at chromosome 19p13, which encodes the Cav2.1 (P/Q-type)
(Ophoff et al., 1996). FHM2 is occasioned by mutations in
the ATP1A2 at chromosome 1q23 (De Fusco et al., 2003). The
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last gene is SCN1A, encoding the α1 subunit of the neuronal
sodium channel, themutation in which leads to FHM3 (Dichgans
et al., 2005). In this review, we describe only mutations in
ATP1A2, as well as the role of glutamate in the development
of FHM. FHM was the first human disease linked to mutations
of the α2 catalytic subunit, which was first demonstrated in
two Italian families (De Fusco et al., 2003). There is also
a linkage between sporadic hemiplegic migraine (SHM) and
mutations in α2 (Thomsen and Olesen, 2004; Kirchmann et al.,
2006), with other brain disorders also associated with α2
mutations.
In the mouse, α2 is expressed in cardiac and skeletal
muscle throughout life. However, in neurons, Atp1a2 is only
expressed during embryonic development (Moseley et al., 2003),
being present in astrocytes and meningeal tissues in adulthood
(McGrail et al., 1991; Watts et al., 1991; Peng et al., 1997).
During neuronal activity, NKA is important for removing K+
from the synaptic cleft. Moreover, it is fundamental for the re-
uptake of released glutamate from the extracellular space, since
active transport of glutamate into neurons and astrocytes is
regulated by Na+ and K+ gradients, emphasizing the importance
of NKA in synaptic regulation (Ransom et al., 2000; D’Ambrosio
et al., 2002; Jorgensen et al., 2003). Atp1a2-deficient embryos
have impaired neurotransmitter clearance, as well as potentiated
neural excitation and cell death, specifically in the amygdala and
piriform cortex. Consequently, heterozygous adult mice show
increased levels of anxiety/fear behaviors, concurrent to raised
levels of c-Fos and increased neuronal activity in the piriform
cortex and amygdala after fear stimuli. This indicates a role for
α2 in regulating not only neural activity (Ikeda et al., 2003), but
also affective processing, including in the role of the amygdala in
cortex development.
Kawakami et al. (2005) reported that heterozygous Atp1a2
mice, α+/−2 KOE21, show spontaneous epileptic seizures. In
addition, their data demonstrated neuronal apoptosis in the
piriform cortex and amygdala (Ikeda et al., 2003), being a
possible explanation as to the manifestation of epilepsy in 20%
of FHM2/SHM families (Bianchin et al., 2010). These epileptic
seizures arise when neurons situated in temporal lobe regions,
including the amygdala, piriform cortex and hippocampus
become hyperexcitable (Aroniadou-Anderjaska et al., 2008).
However, histological changes were not observed in the piriform
cortex and amygdala in the brains of α−/−2 KOE21 knockout
mice (Ikeda et al., 2004). A colocalization of the NKA α2 with
NCX occurs in astrocyte cultures, suggesting a central NKA
role in the modulation of intracellular Ca2+ of the endoplasmic
reticulum (Juhaszova and Blaustein, 1997). In addition, high
levels of intracellular and intra-endoplasmic reticulum Ca2+
ions were detected in cultured astrocytes from Atp1a2-deficient
mice (Golovina et al., 2003), linking NKA α2 to the manifold
consequences of Ca2+ dysregulation.
Mutation in astrocyte NKA α2 facilitates both neuronal
paroxysmal depolarizing shifts and hyper-excitability, triggering
seizures as well as CSD induction and propagation in FHM/SHM
patients (Pietrobon, 2005). Bolay et al. (2002), using an
animal model of migraine, observed that CSD activates a
N-methyl-D-aspartate (NMDA)-dependent pathway leading to
an activation of nociceptive trigeminal afferents in the meninges,
resulting in headache. Additionally, a specific role for NKA
in glutamate clearance during synaptic transmission has also
been established, with NKA being stimulated by glutamate in
astrocyte cultures (Pellerin and Magistretti, 1997). Furthermore,
a colocalization and functional coupling between NKA and
glutamate transporters has also been demonstrated (Rose et al.,
2009), with α2 having a similar perisynaptic glial localization
to the glutamate transporters GLAST and GLT-1in the rat
somatosensory cortex (Cholet et al., 2002; Rose et al., 2009).
As such, inefficient astrocyte glutamate reuptake resulting
in increased cortical excitatory neurotransmission, specifically
as driven by NMDA receptor-dependent transmission during
high-frequency action potential sequences, may enhance the
sensibility to CSD in FHM2 (Tzingounis and Wadiche, 2007).
Wider ionic dysregulation may also be evident, with the
increase of extracellular K+ levels resulting from the impaired
clearance by NKA, and an increase in the intracellular Na+
resulting in an elevation in the intracellular Ca2+ level through
the NCX (Pietrobon, 2005), contributing to wider central
disruption. Moreover, recent data indicates that impaired
glutamate clearance by astrocytes, and involving the α2, is
an important molecular mechanism of FHM2 (Figure 1). This
in vitro study, in a hippocampal mixed astrocyte and neuronal
culture derived from homozygous αG301R/G301R2 E17 embryonic
mice, demonstrated reduced glutamate uptake due to the loss
of functional NKAα2 in astrocytes. Interestingly, in vivo data
in the same study showed a relationship between the glutamate
system and the female sex hormone in psychiatric manifestations
of FHM2. Furthermore, higher glutamate levels were evident
in different brain regions from adult female α+/G301R2 mice,
compared to male mice (Bøttger et al., 2016).
In support of a role for glutamatergic dysregulation in
migraine, MTDH, a regulator of glutamate transporters,
associates with the frequent form of migraine with aura.
Furthermore, amutation in the SLCA3 gene that encodes the glial
excitatory amino acid transporter type 1 (EAAT1) has also been
found, leading to neuronal hyper-excitability and consequent
hemiplegia, as well as seizures and episodic ataxia, which arise
as a consequence of impaired glutamate uptake (Jen et al.,
2005).
Recent studies have demonstrated a link between long-term
memory formation in the rat hippocampus and the astrocyte-
neuron lactate transport (Suzuki et al., 2011). Furthermore,
there is a relationship between NKA and the astrocyte specific
glutamate-dependent transport of lactate (Kleene et al., 2007).
This interesting finding may contribute to the pathophysiological
processes underlying language disorder, cognitive impairment
and mental retardation evident in FHM2/SHM patients (Le
Pira et al., 2004; Kalaydjian et al., 2007). As such, evidence
suggests that the central glutamatergic system has an important
role in driving the consequences of ATP1A2 mutations and
should also be more explored in ATP13A mutations, due to
the diagnostic confusion and overlap with glutamate transporter
diseases.
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Glutamatergic Signaling: a Brief
Introduction
Glutamate is an amino acid, which is considered the main
central excitatory neurotransmitter, being highly abundant in
the majority of animals, especially in the cortex, hippocampus
and caudate nucleus (reviewed in Erecinska and Silver, 1990).
Glutamate’s cellular actions are mediated through the activation
of metabotropic and ionotropic receptors. The ionotropic
receptors are divided according to their affinities for specific
agonists, namely NMDA, AMPA, and kainate (McLennan, 1981).
The glutamatergic metabotropic receptors were first investigated
in late 1980’s (Nicoletti et al., 1986). There are eight types of
metabotropic receptors divided into three groups (Groups I, II,
and III) depending on DNA sequence and the signaling pathway
they activate (reviewed in Wieronska et al., 2016).
Glutamate has many roles, including being part of
intermediary metabolism in the brain (Krebs, 1935; Berl et al.,
1961) as well as acting as a precursor for different compounds,
such as the inhibitory neurotransmitter gamma-aminobutyric
acid (GABA) (Roberts and Frankel, 1950). By acting through
metabotropic and/or ionotropic receptors, glutamate is also an
important element in a variety of core processes such as learning
and memory, partly by regulating synaptic plasticity via long-
term potentiation (LTP) (Bliss and Collingridge, 1993; Vickery
et al., 1997), long-term depression (LTD) (Dudek and Bear,
1992; Yokoi et al., 1996; Nicoll et al., 1998; Dong et al., 2013) or
both (Manahan-Vaughan, 1997; Huang L. Q. et al., 1997; Wang
et al., 2015). The hippocampus and cortex are the major brain
regions investigated in studies of cognition, with these regions
also showing the highest concentrations of brain glutamate.
Glutamate is crucial to many other brain processes, including
motor behavior (Conquet et al., 1994; Pekhletski et al., 1996;
Coesmans et al., 2003; Talpalar and Kiehn, 2010; Ohtani et al.,
2014; Guimaraes et al., 2015), as well as in brain development
(Deisseroth et al., 2004; Poulsen et al., 2005; DeSilva et al., 2012;
Yamasaki et al., 2014; Jantzie et al., 2015).
Abnormalities in glutamate function can arise from alterations
in a variety of factors, including: glutamate transporters and
glutamatergic receptors, as well as glutamate metabolism and
synthesis. Also, changes in the levels of glutamate’s precursor,
glutamine, may drive alterations in the extracellular glutamate
concentration. Inflammation is linked to a host of medical
conditions, with effects linked to sustained glutamate elevations
(Takaki et al., 2012) or changes in glutamatergic receptor
expression (Drouin-Ouellet et al., 2011). Increased levels of
glutamate contribute to inflammatory process, as indicated by
the efficacy of glutamatergic receptor antagonist in reducing
inflammation (Bonnet et al., 2015).
Lack of glutamate could lead to memory deficits, given
that LTP in some brain areas is NMDA receptor-dependent
(Malenka and Bear, 2004). However, excess glutamate can
be excitotoxic to neurons. A number of studies show a
strong correlation between abnormal glutamatergic signaling
pathway and neurodegenerative/psychiatric diseases, including
Alzheimer’s disease (Takahashi et al., 2015; Haas et al., 2016),
Parkinson’s disease (Alvarsson et al., 2015; Morin et al., 2015),
Huntington’s disease (Behrens et al., 2002; Estrada-Sánchez et al.,
2009), amyotrophic lateral sclerosis (Plaitakis et al., 1988; Veyrat-
Durebex et al., 2015), epilepsy (Wong et al., 2015), ischemia
(Dhami et al., 2013), migraine (Peres et al., 2004; Campos et al.,
2013), schizophrenia (Spangaro et al., 2012; Matsuno et al., 2015),
depression (Berman et al., 2000; Duric et al., 2013; Peng et al.,
2016), addiction (Aitta-aho et al., 2012; Perry et al., 2016), and
autism spectrum disorder (Bristot Silvestrin et al., 2013).
NKA and Glutamatergic Signaling
In the mammalian CNS, astrocytes are the most abundant
glial cells. Astrocytes show two different NKA α isoforms, α1
and α2, with α1 being ubiquitously expressed (Geering, 2008).
Under physiological conditions, during excitatory synaptic
activity, astrocytes are responsible for glutamate uptake from
the synaptic space, keeping extracellular levels of glutamate at
nanomolar concentrations, and thereby avoiding the harmful
consequences of glutamate receptor over-stimulation (Rothstein
et al., 1996; Herman and Jahr, 2007; Kirischuk et al., 2012;
Illarionova et al., 2014; Zhang et al., 2016). Astrocytes are
therefore considered significant regulators of glutamatergic
synaptic transmission (Amara and Fontana, 2002; Zhang et al.,
2016). The glial glutamate transporters (GluTs) that mediate
glutamate uptake rely on the NKA electrochemical gradient
(Levy et al., 1998; Anderson and Swanson, 2000; Chatton
et al., 2000; Kanner, 2006). The family of excitatory amino acid
transporters (EAAT) are composed of the glutamate transporters,
with GLAST (glutamate/aspartate transporter or EAAT1) and
GLT-1 (glutamate transporter 1, or EAAT2) being considered
the most important (Tanaka, 2000; Zhang et al., 2016) and the
predominant type of GluT in adult astrocytes (Rothstein et al.,
1996; Dunlop, 2006; Matos et al., 2013). As such, an alteration
in the NKA ionic and electrochemical gradient is intimately
associated with astrocyte regulation of glutamatergic activity.
In the cell, ATP depletion can lead to a reversal (Longuemare
et al., 1999), or inhibition, of glutamate uptake (Sheean et al.,
2013; Shan et al., 2014), as shown by inhibitory doses of OUA,
which impairs glutamate transport (Pellerin and Magistretti,
1997; Rose et al., 2009; Genda et al., 2011) and leads to the
redistribution and clustering of GluTs (Nakagawa et al., 2008;
Nguyen et al., 2010). Some studies indicate a co-localization and
physical interaction between the α2 subunit and GluTs (Cholet
et al., 2002; Rose et al., 2009; Genda et al., 2011; Matos et al., 2013;
Illarionova et al., 2014), suggesting NKA regulation of GluTs by
direct contact, as well as via the electrochemical gradient.
Elevated glutamate concentrations (up to 50 µM) may
stimulate NKA activity (Gegelashvili et al., 2007). This was
observed in a study of human fetal astrocytes, which showed
that during synaptic activity, when glutamate is elevated, there is
an increase in cell membrane expression of the NKA FXYD2/γ
subunit and GLAST, suggesting a possible interaction between
them (Gegelashvili et al., 2007; Nguyen et al., 2010; Zhang
et al., 2016). Furthermore, the inhibition of Src in forebrain
synaptosomes with PP2 or SU6656, as well as the inhibition of
NKA by OUA, both decreased glutamate transport activity to
the same level (Rose et al., 2009), suggesting the existence of a
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possible protein complex formed between NKA/Src/GluT (Rose
et al., 2009).Moreover, adenosine canmodulate glutamate uptake
through activation of astrocyte adenosine A2A receptors (A2ARs),
which can interact with the α2 isoform in the adult mouse brain,
leading to the inhibition of astrocyte glutamate uptake (Matos
et al., 2013). This data strengthens the idea of a macromolecular
complex in astrocytic membranes encompassing A2ARs, α2 and
GLT-I (Matos et al., 2013; Reinhard et al., 2013), with parallels
in neurons. In 2009, Rose and colleagues showed that in the
rat hippocampus GLT-1b isoform is co-expressed with α2 in
astrocytes, whereas GLT-1a isoform was co-expressed with α3, a
neuronal specific isoform (Chen et al., 2004; Bassan et al., 2008;
Furness et al., 2008; González-González et al., 2008; Rose et al.,
2009; Petr et al., 2015).
Notwithstanding the existence of a well described physical
interaction between α2 and GluTs (Cholet et al., 2002; Porras
et al., 2008; Rose et al., 2009; Genda et al., 2011; Bauer et al.,
2012; Matos et al., 2013; Rose and Chatton, 2016), the substantial
Na+ influx that is driven into astrocytes during synaptic activity
has been related to a possible functional interaction, whereby
astrocytes increase the local availability of metabolic substrates
(Rose and Chatton, 2016). During glutamate stimulation, there
is a dramatic reduction in neuronal ATP mediated by NMDA
receptor activation followed by an increase in NKA activity (Foo
et al., 2012).
In the 1990’s, Inoue and Matsui observed an increase in
K+ uptake by α2 and α3 after stimulation of rat embryonic
neurons with glutamate (100 µM) (Inoue and Matsui, 1990).
Similar results were observed some years later in Wistar adult rat
slices (Nathanson et al., 1995; Munhoz et al., 2005) by Munhoz
et al. (2005), which described a pathway whereby glutamate
stimulation of NMDA receptor-NOS leads to increased NKA
activity, possibly due to increased cyclic GMP (cGMP) synthesis.
Glutamate-induced Ca2+ influx leads to the activation of
neuronal nitric oxide synthase (nNOS) and increased production
of nitric oxide (NO). NO, by activating soluble guanylylcyclase
(sGC) enzyme, increases concentrations of the second messenger
cGMP, thereby up-regulating cGMP-dependent protein kinase
(PKG). PKG modulates NKA, altering the activity of NKA
isoforms, both centrally and peripherally (McKee et al., 1994; de
Oliveira Elias et al., 1999; Munhoz et al., 2005; Scavone et al.,
2005). Accordingly, a strong correspondence occurs between
pharmacologically induced cGMP and NKA modulation in the
cerebellum, reinforcing the role of the glutamate-NO-cGMP
pathway in NKA regulation (Nathanson et al., 1995).
In 1999, Inoue and colleagues showed that when primary
neuronal cultures from rat embryos were treated with three
typical agonists of ionotropic glutamate receptors, namely kainic
acid (KA), AMPA and NMDA, a remarkable increase in the
activity of α2 and α3 isoforms and a slight decreased activity of
α1 was observed, suggesting that glutamate effects on NKA may
be mainly mediated by ionotropic glutamate receptors (Inoue
et al., 1999; Kawamoto et al., 2012), with the neuronal NKA
isoforms differing in physiological functions and playing a crucial
role in restoring ion gradients after neuronal excitation (Inoue
et al., 1999).Meanwhile, Brines and Robbins (1992) observed that
prolonged inhibition of α2 and α3 could lead to the potentiation
of glutamate neurotoxicity, with NKA activity also regulating the
cell surface expression and turnover of AMPA receptors (Zhang
et al., 2009). Interestingly, when primary cultured cerebellar
neurons were treated with 0.1 µM glutamate a 37% increase
in NKA activity was observed, while a concentration of 100
µM glutamate was able to increase NKA activity by 85%.
However, when pre-treated with the NMDA receptor antagonist,
MK-801, NKA activity increase was abrogated, suggesting
that glutamate-driven NKA activation is mediated by NMDA
receptors (Marcaida et al., 1996). Once NMDA receptors are
activated, the subsequent Ca2+ influx can activate calcineurin,
a calcium/calmodulin-dependent protein phosphatase (Marcaida
et al., 1996; Rambo et al., 2012; Unoki et al., 2012; de Lores Arnaiz
and Bersier, 2014), which, through NKA dephosphorylation,
restores NKA enzyme activity (Bertorello et al., 1991; Aperia
et al., 1992; Marcaida et al., 1996). It is well proven that protein
kinase C (PKC) phosphorylates the α subunit, leading to a
decrease in its enzyme activity (Bertorello and Aperia, 1989;
Fukuda et al., 1991; Beguin et al., 1994; Marcaida et al., 1996;
Cheng et al., 1997; Chibalin et al., 1998; Nishi et al., 1999; Taub
et al., 2010; Liu et al., 2016). Calcineurin can desensitize NMDA
receptors (Lieberman and Mody, 1994) via the C-terminus of
the NR2A subunit (Krupp et al., 2002) and regulates calmodulin
effects, reducing the open time of the channel (Rycroft and Gibb,
2004).
During learning processes PKC is active and phosphorylates
some Src family kinases (SFK), which in turn induces tyrosine
phosphorylation of NMDA receptors, leading to a rapid up-
regulation of NMDA receptor membrane expression (Groveman
et al., 2012). Some studies have proposed that Src protein
forms a complex with the NMDA receptor through the
binding of its SH2 domain with the N-terminal region of
postsynaptic density protein 95 (PSD-95). Furthermore, PSD-95
seems to negatively regulate Src (Kalia et al., 2006; Groveman
et al., 2012). Indeed, co-activation of mGluR5 and the NMDA
receptor with low concentrations of their agonists (CHPG
and NMDA, respectively), in rat hippocampal slices, leads
to the phosphorylation of NR2B (Tyr1472) by Src kinase
(Sarantis et al., 2015), in turn increasing NMDA-mediated
excitability.
It is important to note that NKA acts as a specific receptor
for CTS. The interplay between the NKA and NMDA receptors
is proposed to arise from the initial administration of CTS
leading to conformational changes that enhance NMDA subunit
expression as a compensatory mechanism (de Lores Arnaiz and
Bersier, 2014). OUA is also able to regulate NMDA binding and
receptor activity in the adult rat brain (Reines et al., 2001, 2004;
Bersier and Rodríguez de Lores Arnaiz, 2009), in a concentration-
dependent manner (Bersier and Rodríguez de Lores Arnaiz,
2009). Akkuratov et al. (2015), in rat cerebellar neurons, showed
that both α1 and α3 subunits can functionally interact with
NMDA receptors whereas Sibarov and colleagues demonstrated
by patch-clamp and Ca2+ imaging experiments that rat cortical
neurons treated with 30 µM NMDA or KA with 1 nM OUA or
digoxin for 4 or 6 h, were protected from apoptosis (Sibarov et al.,
2012; Abushik et al., 2013). Similar protection was observed in
vivo (Golden and Martin, 2006). One possible explanation is that
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an up-regulation of the plasma membrane NCX leads to more
Ca2+ extrusion preventing the increase of sEPSC frequency,
which is typically found in excitotoxicity process. This up-
regulation of NCX activity seems to be due to an interaction
between NKA and NCX (Sibarov et al., 2012).
Furthermore, a study published in 2013, in primary cerebellar
cell culture treated with OUA in different concentrations (1, 10,
and 100mM) for different times (1, 2, and 4 h), suggested nuclear
factor-kappaB (NF-κB) activation in a time and concentration-
dependent manner. However, this effect was not observed
when neurons were pre-treated with MK-801, PP1 (Src-family
tyrosine kinase inhibitor), manumycin A (farnesyltransferase
inhibitor), and PD98059 (mitogen-activated protein kinase
(MAPK) inhibitor). As such, this study described a pathway
whereby OUA activates NF-κB through the NMDA receptor-
Src-Ras-MAPK pathways (de Sá Lima et al., 2013). Strong
evidence indicates that NMDA can activate NF-κB in the rat
hippocampus (Lipsky et al., 2001; Kawamoto et al., 2012), with
intra-hippocampal injection of 1 µM NMDA 1 h before the
injection of 10 nM OUA potentiating NF-κB activity (Kawamoto
et al., 2012). This activation was reduced when cells were pre-
treated with anNMDA receptor antagonist (MK-801), suggesting
that NF-κB activation by OUA, in part, arises from NMDA
receptor modulation (Kawamoto et al., 2012). Overall, the above
results indicate that OUA, through the action of NKA as a
pump or as a receptor, can modulate many signals important in
neurotransmission.
NKA-Glutamatergic Signaling: Aging and
Neurodegenerative Diseases
Several studies have shown age-related modifications in the
NMDA receptor-NO-cGMP cascade in the CNS (Peterson
and Cotman, 1989; Tamaru et al., 1991; Wenk et al., 1991;
Vallebuona and Raiteri, 1995; Wardas et al., 1997; Ossowska
et al., 2001; Chepkova et al., 2015). In addition, the aging process
is associated with a progressive decline in NKA activity, both
centrally and peripherally (Scavone et al., 2000; Kawamoto et al.,
2008; Vasconcelos et al., 2015). In the CNS, this reduction
is due to the modulation of α2 and α3 isoforms with no
change in α1 and Mg2+-ATPase activities, as reported in
the rat cerebellum and hippocampus (Kawamoto et al., 2008;
Vasconcelos et al., 2015). As no differences in the α2 and α3
protein levels are evident, the age-related decrease in NKA
activity is linked to modifications in glutamate-cGMP-PKG
pathway (Kawamoto et al., 2008). The age-related failure of NKA
modulation by glutamate through cGMP-PKG signaling may be
connected to ionic disturbances during senescence, which may
predispose to neurodegenerative diseases (Scavone et al., 2005).
Interestingly, while inflammation, closely associated with aging
and neurodegeneration, worsens aging-associated glutamate
signaling and NKA defects, intermittent fasting counteracts this
effect (Vasconcelos et al., 2015) (Figure 2).
DNA repair defects (Garinis et al., 2008; Schumacher
et al., 2008; Végh et al., 2012), and consequent mitochondrial
dysfunction (Zahn et al., 2007; Yankner et al., 2008), are
considered important causes of aging and, in turn, with
neurodegenerative disorders (Lin and Beal, 2006; Johri and Beal,
2012). Likewise, ROS-induced mitochondria impairment may
contribute to the etiology of neurodegenerative disorders (Lin
and Beal, 2006). Compromised mitochondria lead to impaired
energy supply, producing less ATP and even more free radicals,
as a consequence of inefficient oxidative phosphorylation, which,
in turn, can directly or indirectly affect NKA activity (Nathanson
et al., 1995). In support of this, a number of studies show the
α subunit to be sensitive to free radical attack (Kim and Akera,
1987; Mense et al., 1997; Xie and Xie, 2005), with the oxidized
α subunit being degraded (Zolotarjova et al., 1994; Thevenod
and Friedmann, 1999). Furthermore, age-related increases in
the levels of the free radical superoxide (O−2 ) lead to ONOO
−
formation via reaction with the NO generated by glutamate
signaling (Wink et al., 1996). ONOO− also impairs NKA
activity (Boldyrev et al., 1997; Sato et al., 1997; Muriel and
Sandoval, 2000; Kocak-Toker et al., 2005; Reifenberger et al.,
2008). NKA inhibition also increases neuronal susceptibility
to glutamate excitotoxicity, at least in part by reducing the
Na+ gradient necessary for glutamate transport and clearance
from the synapse cleft, leading to a positive feedback loop
(Lees et al., 1990; Brines and Robbins, 1992). Both cGMP and
PKG are well-established as important mediators of LTP, which
NKA also modulates (Stevens and Wang, 1993; Zhuo et al.,
1994; Nathanson et al., 1995). Moreover, NKA impairment
downregulates the synaptic AMPA receptor, contributing to
synaptic transmission defects, and consequently cognitive decline
(Zhang et al., 2009). Since cognitive impairment is a hallmark of
aging and neurodegenerative diseases, NKA-mediated glutamate
signaling dysfunctionmay be an important contributory factor to
neurodegenerative disorders (Végh et al., 2012).
EAAT downregulation has been associated with many
neurodegenerative diseases (Sheldon and Robinson, 2007). As
described above, the resulting elevation in glutamate levels in the
synapse cleft and consequent excitotoxicity may interfere in NKA
functioning by increasing NO release and free-radical production
(Dawson et al., 1991).
Glutamatergic signaling dysfunction and its associated
consequences are critical contributors to the pathophysiological
underpinnings of Alzheimer’s disease (AD) (Lewerenz and
Maher, 2015). AD is the most frequent form of dementia,
being characterized by memory and cognitive impairments. The
AD brain shows two classical changes: increased Aβ peptide
deposition in senile plaques; and tau hyperphosphorylation that
leads to neurofibrillary tangles (Khachaturian, 1985; Mattson,
2004). AD is also associated with increased ROS production
(Butterfield et al., 2001), compromised glutamate clearance
(Lauderback et al., 2001; Vitvitsky et al., 2012) and increased
immune-inflammatory activity, in association with raised levels
of glutamate, which regulates tryptophan catabolites (Maes and
Anderson, 2016).
ATPase activities play a key role in protecting neurons from
excitotoxic insults (Hattori et al., 1998). Hattori and colleagues
showed reduced NKA activity in postmortem AD patients’
brains (77.2% of the controls) with no change in Mg2+-ATPase
activities (Hattori et al., 1998). The protein levels of alpha and
beta subunits were also decreased in AD brains (Hattori et al.,
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FIGURE 2 | Schematic model for molecular mechanisms underlying aging modulatory effects on NKA isoforms. Aging can either increase the production
of ROS, such as superoxide radical and hydrogen peroxide, or induce NO• release by impairing Ca2+ homeostasis and subsequently increasing intracellular Ca2+
(nNOS-mediated NO• production). NO• is a free radical and can generate peroxynitrite, which may cause neurotoxicity by lipid peroxidation, mitochondria disruption,
mutations of DNA and proteins, apoptosis and impairment of α1 activity. Strategies that induce NMDA activation can also activate the cGMP pathway, which, in turn,
may lead to neuroprotective signaling, partly by upregulating α2 and α3 (cGMP, cyclic GMP; GLU, glutamate; NKA, Na+,K+-ATPase).
1998). However, although this study showed a clear reduction
of NKA activity in the frontal lobes of AD brains (Hattori
et al., 1998), a previous study found no change in NKA enzyme
activity in 4 AD brains vs. 5 control brains (Liguri et al.,
1990).
In an in vitro study, the acute administration of Aβ25−35 or
Aβ1−40 oligomers in rat hippocampal neurons resulted in lower
NKA activity (Mark et al., 1995), suggesting a role of Aβ toxicity
in the NKA activity impairment. Also, a disruption in NKA
activity leads to Na+ intracellular accumulation, increasing the
influx of calcium through voltage-dependent calcium channels
(Mark et al., 1995), suggesting an NKA role in AD cellular
toxicity and apoptosis (Hattori et al., 1998). In an AD model,
the APP+PS1 transgenic mouse, a decrease in hippocampal NKA
activity and protein levels is also evident (Dickey et al., 2005),
further implicating a role for Aβ regulation of NKA in AD.
Supporting the NKA dysfunction in AD, Vitvitsky and
colleagues showed an imbalance of Na+ and K+ ion
concentrations in both postmortem AD brain tissue and in
vitro primary astrocytes treated with Aβ25−35 or Aβ1−40peptides
(Vitvitsky et al., 2012). The electrochemical Na+ gradient
maintained by NKA is the driving force for glutamate re-uptake
by EAATs (Rose et al., 2009). In the astrocyte cell culture, ion
homeostasis disruption was associated with reduced levels
of NKA and Na+-dependent EAATs (Vitvitsky et al., 2012).
Furthermore, homocysteine, a protein involved in many CNS
disorders, including Parkinson’s disease (Kuhn et al., 1998)
and AD (Gallucci et al., 2004), was shown to reduce NKA
activity and consequently impair glutamate reuptake in the rat
hippocampus (Machado et al., 2011). Hence, NKA impairment
associated with glutamate signaling imbalance may contribute
to the pathophysiology of AD and other neurodegenerative
diseases by significantly deregulating membrane transport,
brain electrophysiological activity and other important cellular
processes (Vitvitsky et al., 2012).Huntington’s disease (HD) is
another neurodegenerative disorder associated with cognitive
decline and synapse impairment (DiFiglia et al., 1995; Smith
et al., 2005; Rozas et al., 2010; Nithianantharajah and Hannan,
2013; Valencia et al., 2013). Many studies show glutamate
signaling to be defective in HD, which is proposed to play a role
in its pathophysiology (Coyle and Schwarcz, 1976; Beal et al.,
1986; Zeron et al., 2002; Shehadeh et al., 2006). In Hdh140Q/140Q,
a knock-in mouse model of HD, a reduction of NKA and
glutamate transporters, VGlut1 and Vglut2, by more than 30% is
evident at 12 months vs. controls (Valencia et al., 2010, 2013).
Amyotrophic lateral sclerosis (ALS) is an age-related fatal
disease characterized by progressive motoneuron degeneration.
The loss of Cu/Zn superoxide dismutase 1 (SOD1) activity,
an antioxidant enzyme, following increased oxidative stress, is
widely thought to have a role in the etiology and/or course of
ALS (Julien, 2001). Other possible contributing factors include
increases in iNOS (Almer et al., 1999), glutamate excitotoxicity
due to EAATs dysfunction (Rothstein et al., 1995; Bruijn et al.,
1997; Trotti et al., 1999) and mitochondrial defect (Beal, 1995).
Importantly, Ellis et al. showed that the NO-sGC-cGMP pathway
was significantly impaired in the transgenic SOD1 ALS murine
model, with this cascade being unable to modulate NKA activity
(Ellis et al., 2003). Furthermore, in this study, a marked reduction
in NKA activity accompanied by a decrease in the protein levels
of the α subunits was evident. As to whether such changes are
causal or a consequence of other pathophysiological processes in
ALS requires further investigation (Ellis et al., 2003).
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CONCLUSIONS AND FUTURE
PERSPECTIVE
NKA is present in the membranes of most eukaryotic cells
and acts as ion pump. NKA can be modulated by hormones
and neurotransmitters, allowing these factors to regulate NKA’s
diverse important effects, including in the regulation of
neurotransmission. NKA can also act as a receptor for steroids, as
typified by the effects of OUA, with this being anothermechanism
whereby it contributes to the regulation of many essential cellular
functions, centrally and peripherally. Changes in NKA activity,
as occurs in aging as well as when arising from mutations, will
play a role in a host of CNS diseases, partly via deficits in energy
and glutamatergic regulation. Central energy deficiency has been
proposed to be a key factor in many, currently poorly managed,
neurodegenerative diseases, which are linked to changes in
brain metabolism and increased levels of apoptosis. Given that
NKA is fundamental for optimizing central synaptic functioning,
as well as energy regulation, its further study, including its
environmental, epigenetic and genetic regulation, are likely to
be important in the development of new pharmacological and
non-pharmaceutical treatments for a host of medical conditions
that are currently poorly managed, as well as for the study and
regulation of aging per se.
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